Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics Inc (NQ: AGRX )

2.100 +0.080 (+3.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agile Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group
Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research.... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
Via ACCESSWIRE
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
On August 9, Agile Therapeutics (NASDAQ: AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly bi 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
Via ACCESSWIRE
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
Via ACCESSWIRE
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions Of Women Thanks To A Partnership With Afaxys
Agile Therapeutics, Inc.’s (NASDAQ: AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women’ 
Via Benzinga
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
This month, Agile Therapeutics, Inc. (NASDAQ: AGRX) announced partnerships with FPA Women’s Health and 
Via Benzinga
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage
Via ACCESSWIRE
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage
In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services. 
Via Benzinga
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
Via ACCESSWIRE
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Via ACCESSWIRE
Why Tattooed Chef Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket
Gainers Micromobility.com Inc. (NASDAQ: MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently reported a strategic realignment to strengthen its financial position and... 
Via Benzinga
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?
Via ACCESSWIRE
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ: AGRX) this month, setting a price target of $12 per share. 
Via Benzinga
The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care
Via ACCESSWIRE
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Agile Therapeutics (NASDAQ: AGRX) announced the closing of its public offering in May. 
Via Benzinga
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
From Agile Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
Agile Therapeutics – This Women's Healthcare Company's "Skinfusion" Technology Sets It Apart From Other Contraceptive Companies
Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently interviewed by Benzinga.  
Via Benzinga
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
From Agile Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
Why Agile Therapeutics Stock Is Trading Higher Today
Agile Therapeutics Inc (NASDAQ: AGRX) announced an agreement with vitaCare Prescription Services, a wholly owned subsidiary of GoodRx Holdings Inc (NASDAQ: GDRX), to expand patient access and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.